Aarti Drugs Ltd. Q1 FY27 Results

Revenue up 19% to ₹703.6 crore; EBITDA jumps 30% to ₹96.9 crore.

Reader Takeaway: Strong revenue and EBITDA growth with margin expansion offset by a one-time prior-year tax benefit impacting PAT.

What just happened

Aarti Drugs Ltd. announced its financial results for the first quarter of fiscal year 2027 (Q1 FY27). The company reported a consolidated revenue of ₹703.6 crore, marking a significant 19% increase compared to ₹590.8 crore in Q1 FY26. EBITDA saw a substantial jump of 30%, reaching ₹96.9 crore from ₹74.4 crore in the previous year's quarter. EBITDA margins improved by 120 basis points to 13.8% from 12.6%.

Profit After Tax (PAT) for the quarter stood at ₹50.1 crore, a 7% decrease from ₹54.0 crore in Q1 FY26. The company attributed this year-on-year PAT decline partly to a significant one-time principal tax refund of approximately ₹15 crore received in the corresponding quarter of the previous fiscal year.

A ₹2 crore write-off related to Capital Work-in-Progress (CWIP) also impacted profitability in Q1 FY27.

Why this matters

The strong revenue and EBITDA growth indicates healthy demand for Aarti Drugs' products and improved operational efficiency. The expansion in EBITDA margins is a positive sign, showcasing the company's ability to manage costs and pricing effectively. While PAT appears lower, understanding the impact of the one-time tax refund is crucial for assessing the underlying business performance.

The backstory

Aarti Drugs operates 14 manufacturing facilities across Maharashtra, Gujarat, and Himachal Pradesh. The Sayakha facility is in a planned ramp-up phase, operating at nearly 65% capacity. The company is also investing in expanding its oral solid dosage (OSD) manufacturing capabilities at Baddi, Himachal Pradesh, aiming to double production capacity in this segment.

What changes now

Investors can anticipate continued focus on scaling operations, particularly with the ongoing capacity expansion in the OSD segment. The performance of the API and Specialty Chemicals segments will remain key drivers. The company's ability to navigate global volatility will be closely watched.

Risks to watch

Management has highlighted the uncertain and volatile global environment as a potential risk factor. Additionally, the company has made a ₹2 crore write-off related to Capital Work-in-Progress in the current quarter.

Peer comparison

While specific peer data is not provided in the filing, Aarti Drugs operates in the competitive pharmaceutical ingredients and specialty chemicals sector. Companies in this space often face pricing pressures and regulatory scrutiny. Aarti Drugs' focus on expanding API and OSD capacities aims to strengthen its market position.

Context metrics (time-bound)

• Q1 FY27 Revenue: ₹703.6 crore (vs. ₹590.8 crore in Q1 FY26)
• Q1 FY27 EBITDA: ₹96.9 crore (vs. ₹74.4 crore in Q1 FY26)
• Q1 FY27 EBITDA Margin: 13.8% (vs. 12.6% in Q1 FY26)
• Q1 FY27 PAT: ₹50.1 crore (vs. ₹54.0 crore in Q1 FY26)
• Sayakha Facility Utilization: ~65% in Q1 FY27

What to track next

Investors should monitor the ramp-up progress of the Sayakha manufacturing facility and the execution of the Baddi capacity expansion project. The company's performance in its key segments – API and Specialty Chemicals – will be critical. Tracking the company's response to global market volatility will also be important.